Fig. 5.
![Fig. 5. Only huCD64 Tg mice treated with G-CSF are protected by [huCD64 × Id] BsAb. / Groups of 5 age-matched mice received a treatment schedule as shown in Figure 3 using BCL1 lymphoma cells. However, mice were either huCD64 Tg (c, d) or nonTg littermates (a, b) that were (b, d) or were not (a, c) given 10 days of recombinant G-CSF. Antibody-treatment was as indicated: PBS (●), anti-Id IgG (▵), [huCD64 × Id] (○). Survival was recorded daily. Similar results were obtained with the A31 model, but in this case the IgG anti-Id gave approximately 50 days protection in all groups (not shown).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347005.jpeg?Expires=1725294606&Signature=Hl1gs3nvsT8yUNILYjHFbcAdHW8YG0FXj9b6s8SR-aHH7raiD5m2UH4GqrOsUe6i8gjPyHsjWvvTu0oJyO5gPCZtnL9VweY9hyLbqAleklH5pqfqhnuopX1cHGNsM6emY2s3MIFomYUrnu6O4TgDK61Np9CHR8WqMz2Puy-eoeqWj4kWYnLCTyrbZ~xvdonSLOSza~dzwFT1Wf0pHOEDSBA-RhD6Bms1ZJGsZ5E7O9sGK-7JjEgeOVQ2CcO4yAyaQrygRKeIJVfXZXhlDTEnKV8LhsiScfnJwO-sO0W8iHuXWVw-jlOKuQcKr0Vz1SWLr8azLDv1ucD6cNznXMEhgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Only huCD64 Tg mice treated with G-CSF are protected by [huCD64 × Id] BsAb.
Groups of 5 age-matched mice received a treatment schedule as shown in Figure 3 using BCL1 lymphoma cells. However, mice were either huCD64 Tg (c, d) or nonTg littermates (a, b) that were (b, d) or were not (a, c) given 10 days of recombinant G-CSF. Antibody-treatment was as indicated: PBS (●), anti-Id IgG (▵), [huCD64 × Id] (○). Survival was recorded daily. Similar results were obtained with the A31 model, but in this case the IgG anti-Id gave approximately 50 days protection in all groups (not shown).
